|
|
|
Scientific Literature, ankylosing spondylitis
-
Ackermann C, Kavanaugh A 2007 Tumor necrosis factor as a therapeutic target of rheumatologic disease.
Expert Opin. Ther. Targets 11: 1369-1384.
-
Adam O 2008 Ankylosing spondylitis and convenient nutrition.
Wien. Med. Wochenschr. 158: 294-297.
-
Adam R, Sturrock RD, Gracie JA 2006 TLR4 mutations (Asp299Gly and Thr399Ile) are not associated with ankylosing spondylitis.
Ann. Rheum. Dis. 65: 1099-1101.
*
-
Adarichev VA, Glant TT 2006 Experimental spondyloarthropathies: animal models of ankylosing spondylitis.
Curr. Rheumatol. Rep. 8: 267-274.
-
Agirbasli M, Inanc N, Baykan OA, Direskeneli H 2006 The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders.
Clin. Exp. Rheumatol. 24: 580-583.
-
Agrawal D, Rukkannagari S, Kethu S 2007 Pathogenesis and clinical approach to extraintestinal manifestations of inflammatory bowel disease.
Minerva Gastroenterol. Dietol. 53: 233-248.
-
Agrawal S, Srivastava R, Sharma B, Pandya S, Misra R, Aggarwal A 2008 IL1RN*2 allele of IL-1receptor antagonist VNTR polymorphism is associated with susceptibility to anklyosing spondylitis in Indian patients.
Clin. Rheumatol. 27: 573-576.
*
-
Aguillon JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M 2006 Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution?
Immunobiology 211: 75-84.
-
Ahmad K, Rogers S 2007 Two years of experience with etanercept in recalcitrant psoriasis.
Br. J. Dermatol. 156: 1010-1014.
*
-
Akkoc N, van der Linden S, Khan MA 2006 Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
Best Pract. Res. Clin. Rheumatol. 20: 539-557.
-
Alaez C, Gazit E, Ibarrola B, Yaron M, Livneh A, Avishai O, Gorodezky C 2007 Distribution of HLA-B27 subtypes in ankylosing spondylitis in an Israeli population.
Arch. Med. Res. 38: 452-455.
-
Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA 2004 Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002.
Rheumatology (Oxford) 43: 615-618.
*
-
Aletaha D, Smolen JS 2006 The definition and measurement of disease modification in inflammatory rheumatic diseases.
Rheum. Dis. Clin. North Am. 32: 9-44.
-
Alexander K, Edwards C, Misko IS, Geczy AF, Bashir HV, Edmonds JP 1981 The distribution of a specific HLA-B27-associated cell surface component on the tissues of patients with ankylosing spondylitis.
Clin. Exp. Immunol. 45: 158-164.
*
-
Alexis AF, Strober BE 2005 Off-label dermatologic uses of anti-TNF-a therapies.
J. Cutan. Med. Surg. 9: 296-302.
-
Aloush V, Ablin JN, Reitblat T, Caspi D, Elkayam O 2007 Fibromyalgia in women with ankylosing spondylitis.
Rheumatol. Int. 27: 865-868.
*
-
Alric L, Laroche M, Faucheux JM, Bonnet E, Massip P, Duffaut M 1997 Systemic manifestations of hemorrhagic rectocolitis: apropos of a case of hemorrhagic rectocolitis associated with multiple sclerosis.
Rev. Med. Interne. 18: 132-137.
-
Althoff CE, Hermann KG, Braun J, Sieper J 2006 Ankylosing spondylitis - current state of imaging including scoring methods.
Z. Rheumatol. 65: 688-699.
-
Alvarez I, Lopez de Castro JA 2000 HLA-B27 and immunogenetics of spondyloarthropathies.
Curr. Opin. Rheumatol. 12: 248-253.
-
Amberger M, Groll S, Gunaydin I, Deuter C, Vonthein R, Kotter I 2007 Intracellular cytokine patterns in Behcet's disease in comparison to ankylosing spondylitis - influence of treatment with interferon-alpha2a.
Clin. Exp. Rheumatol. 25: S52-S57.
-
Amroun H, Djoudi H, Busson M, Allat R, El Sherbini SM, Sloma I, Ramasawmy R, Brun M, Dulphy N, Krishnamoorthy R, Toubert A, Charron D, Abbadi MC, Tamouza R 2005 Early-onset ankylosing spondylitis is associated with a functional MICA polymorphism.
Hum. Immunol. 66: 1057-1061.
-
Andus T, Stange EF, Hoffler D, Keller-Stanislawski B 2003 Suspected cases of severe side effects after infliximab (Remicade) in Germany.
Med. Klin. (Munich) 98: 429-436.
-
Anshu A, Chee SP 2007 Posterior scleritis and its association with HLA B27 haplotype.
Ophthalmologica 221: 275-278.
-
Antoniv TT, Ivashkiv LB 2006 Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages.
Arthritis Rheum. 54: 2711-2721.
*
-
Aoyagi S, Akashi H, Kawara T, Ishihara K, Tanaka A, Kanaya S, Koga Y, Ishikawa R 1998 Aortic root replacement for Takayasu arteritis associated with ulcerative colitis and ankylosing spondylitis - report of a case.
Jpn. Circ. J. 62: 64-68.
-
Archer JR 1981 Search for cross-reactivity between HLA B27 and Klebsiella pneumoniae.
Ann. Rheum. Dis. 40: 400-403.
*
-
Armagan O, Ekim A, Dinc A, Oner C 2007 Ankylosing spondylitis in a patient with Turner syndrome: a case report.
Rheumatol. Int. 27: 1177-1180.
*
-
Armas JB, Gonzalez S, Martinez-Borra J, Laranjeira F, Ribeiro E, Correia J, Ferreira ML, Toste M, Lopez-Vazquez A, Lopez-Larrea C 1999 Susceptibility to ankylosing spondylitis is independent of the Bw4 and Bw6 epitopes of HLA-B27 alleles.
Tissue Antigens 53: 237-243.
*
-
Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A 2008 Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine.
Clin. Rheumatol. 27: 377-380.
*
-
Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, Sieper J 2005 HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis.
Arthritis Rheum. 52: 892-901.
*
-
Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F 2005 Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review.
Autoimmun. Rev. 4: 144-152.
-
Avalos P, Camacho FM 2008 Practical management of adalimumab.
Actas. Dermosifiliogr. 99 Suppl. 3: 25-27.
-
Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H 2008 Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment.
Rheumatology (Oxford) 47: 142-144.
-
Azuz-Lieberman N, Markel G, Mizrahi S, Gazit R, Hanna J, Achdout H, Gruda R, Katz G, Arnon TI, Battat S, Zamir E, Adawi M, Mader R, Mandelboim O 2005 The involvement of NK cells in ankylosing spondylitis.
Int. Immunol. 17: 837-845.
-
Badelon I 1999 Eye and spondylarthropathies.
Rev. Prat. 49: 1995-1998.
-
Baines M, Ebringer A 1992 HLA and disease.
Mol. Aspects Med. 13: 263-378.
-
Bakland G, Nossent HC, Gran JT 2005 Incidence and prevalence of ankylosing spondylitis in Northern Norway.
Arthritis Rheum. 53: 850-855.
*
-
Baldry C, Backman SB, Metrakos P, Tchervenkov J, Barkun J, Moore A 2000 Liver transplantation in a Jehovah's Witness with ankylosing spondylitis.
Can. J. Anaesth. 47: 642-646.
-
Banares A, Hernandez-Garcia C, Fernandez-Gutierrez B, Jover JA 1998 Eye involvement in the spondyloarthropathies.
Rheum. Dis. Clin. North Am. 24: 771-784, ix.
-
Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J 2007 Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.
Rheumatology (Oxford) 46: 1450-1453.
*
-
Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J 2008 The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.
Arthritis Res. Ther. 10: R104.
*
-
Bardazzi G, Mannoni A, d'Albasio G, Bonanomi AG, Trallori G, Benucci M, Serni U, Pacini F 1997 Spondyloarthritis in patients with ulcerative colitis.
Ital. J. Gastroenterol. Hepatol. 29: 520-524.
-
Bayley JP, Ottenhoff TH, Verweij CL 2004 Is there a future for TNF promoter polymorphisms?
Genes Immun. 5: 315-329.
*
-
Becker H, Gaubitz M, Domschke W, Kucharzik T 2006 Joint involvement in chronic inflammatory bowel disease - current diagnostics and treatment options.
Z. Gastroenterol. 44: 497-502.
-
Begovich AB, Chang M, Caillier SJ, Lew D, Catanese JJ, Wang J, Hauser SL, Oksenberg JR 2007 The autoimmune disease-associated IL12B and IL23R polymorphisms in multiple sclerosis.
Hum. Immunol. 68: 934-937.
-
Bellissimo S, Ferrucci MG, Gallo A, Stisi S 2007 Response to anti-TNF-alpha treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis.
Reumatismo 59: 240-243.
-
Beltrami A, Rossmann M, Fiorillo MT, Paladini F, Sorrentino R, Saenger W, Kumar P, Ziegler A, Uchanska-Ziegler B 2008 Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes.
J. Biol. Chem. Jul 23 [Epub ahead of print].
*
-
Ben Radhia K, Ayed-Jendoubi S, Sfar I, Ben Romdhane T, Makhlouf M, Gorgi Y, Ayed K 2008 Distribution of HLA-B*27 subtypes in Tunisians and their association with ankylosing spondylitis.
Joint Bone Spine 75: 172-175.
-
Bergfeldt L 1997 HLA-B27-associated cardiac disease.
Ann. Intern. Med. 127: 621-629.
-
Bernstein CN 2002 Treatment of the extraintestinal manifestations of inflammatory bowel disease.
Curr. Gastroenterol. Rep. 4: 513-516.
-
Bernstein CN 2002 Osteoporosis and other complications of inflammatory bowel disease.
Curr. Opin. Gastroenterol. 18: 428-434.
-
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N 2001 The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.
Am. J. Gastroenterol. 96: 1116-1122.
*
-
Bernstein CN, Wajda A, Blanchard JF 2005 The clustering of other chronic inflammatory diseases in IBD: a population-based study.
Gastroenterology 129: 827-836.
*
-
Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK 1996 Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.
Ann. Rheum. Dis. 55: 66-68.
*
-
Bingham WF 1977 The role of HLA B27 in the diagnosis and management of low-back pain and sciatica.
J. Neurosurg. 47: 561-566.
-
Birinci A, Bilgici A, Kuru O, Durupinar B 2006 HLA-B27 polymorphism in Turkish patients with ankylosing spondylitis.
Rheumatol. Int. 26: 285-287.
*
-
Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D, Einarsdottir AS, Sherwood R, Kristjansson K, Kjartansson O, Thjodleifsson B 2003 Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis.
Gastroenterology 125: 1598-1605.
*
-
Blanco P, Viallard JF, Pellegrin JL, Moreau JF 2005 Cytotoxic T lymphocytes and autoimmunity.
Curr. Opin. Rheumatol. 17: 731-734.
-
Blankenberg-Sprenkels SH, Fielder M, Feltkamp TE, Tiwana H, Wilson C, Ebringer A 1998 Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis.
J. Rheumatol. 25: 743-747.
-
Bockermann R, Schubert D, Kamradt T, Holmdahl R 2005 Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomerase.
Arthritis Res. Ther. 7: R1316-R1324.
*
-
Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T, Gunaydin R, Kuran B, Kotevoglu N, Bal A, Aydog E, Altay Z, Ugurlu H, Kocabas H, Olmez N, Yazgan P, Gursoy S, Madenci E, Ozel S, Delialioglu SU 2008 Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.
Clin. Rheumatol. 27: 1119-1125.
*
-
Boonen A, van der Linden SM 2006 The burden of ankylosing spondylitis.
J. Rheumatol. Suppl. 78: 4-11.
-
Borgiani P, Vallo L, D'Apice MR, Giardina E, Pucci S, Capon F, Nistico S, Chimenti S, Pallone F, Novelli G 2002 Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population.
Eur. J. Dermatol. 12: 540-542.
-
Bouros D, Pneumatikos I, Tzouvelekis A 2008 Pleural involvement in systemic autoimmune disorders.
Respiration 75: 361-371.
-
Bowness P 2002 HLA B27 in health and disease: a double-edged sword?
Rheumatology (Oxford) 41: 857-868.
*
-
Bowness P, Zaccai N, Bird L, Jones EY 1999 HLA-B27 and disease pathogenesis: new structural and functional insights.
Expert Rev. Mol. Med. 1: 1-10.
*
-
Bradley J 2008 TNF-mediated inflammatory disease.
J. Pathol. 214: 149-160.
*
-
Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J 2004 Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-a fusion receptor protein etanercept.
J. Rheumatol. 31: 531-538.
-
Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J 2005 Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Rheumatology (Oxford) 44: 342-348.
*
-
Brandt J, Listing J, Sieper J, Rudwaleit M, Van Der Heijde D, Braun J 2004 Development and preselection of criteria for short-term improvement after anti-TNFalpha therapy in ankylosing spondylitis.
Ann. Rheum. Dis. 63: 1438-1444.
*
-
Bratcher JM, Korelitz BI 2006 Toxicity of infliximab in the course of treatment of Crohn's disease.
Expert Opin. Drug Saf. 5: 9-16.
-
Braun J 2004 Epidemiology and prognosis of ankylosing spondylitis.
Radiologe 44: 209-210, 212-216.
-
Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J 2007 Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Arthritis Rheum. 57: 639-647.
*
-
Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Soerensen H, Zeidler H, Sieper J 2008 Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years - evidence for different types of response.
Ann. Rheum. Dis. 67: 340-345.
*
-
Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J 1998 Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.
Arthritis Rheum. 41: 58-67.
*
-
Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E 2001 New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.
Curr. Opin. Rheumatol. 13: 245-249.
-
Braun J, Sieper J 2006 Early diagnosis of spondyloarthritis.
Nat. Clin. Pract. Rheumatol. 2: 536-545.
*
-
Braun J, Sieper J 2003 Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases.
Expert Opin. Biol. Ther. 3: 141-168.
-
Braun J, Sieper J 2006 Spondylarthritides.
Z. Rheumatol. 65: 613-632.
-
Braun J, Sieper J 2004 Biological therapies in the spondyloarthritides - the current state.
Rheumatology (Oxford) 43: 1072-1084.
*
-
Braun J, van der Heijde D 2003 Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.
Expert Opin. Investig. Drugs 12: 1097-1109.
-
Braun J, Zochling J, Baraliakos X, Alten RH, Burmester GR, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gomor B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J 2006 Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomized controlled trial.
Ann. Rheum. Dis. 65: 1147-1153.
*
-
Braun WE 1992 HLA molecules in autoimmune diseases.
Clin. Biochem. 25: 187-191.
-
Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A 2008 Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Isr. Med. Assoc. J. 10: 277-281.
-
Breban M, Miceli-Richard C, Zinovieva E, Monnet D, Said-Nahal R 2006 The genetics of spondyloarthropathies.
Joint Bone Spine 73: 355-362.
-
Breedveld FC 2005 Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept.
Ned. Tijdschr. Geneeskd. 149: 2273-2277.
-
Brewerton DA 2003 Discovery: HLA and disease.
Curr. Opin. Rheumatol. 15: 369-373.
-
Briot K, Gossec L, Kolta S, Dougados M, Roux C 2008 Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
J. Rheumatol. 35: 855-861.
-
Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L 2007 TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
Joint Bone Spine 74: 148-154.
-
Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB 1993 Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
J. Exp. Med. 178: 879-887.
-
Brophy S, Hickey S, Menon A, Taylor G, Bradbury L, Hamersma J, Calin A 2004 Concordance of disease severity among family members with ankylosing spondylitis?
J. Rheumatol. 31: 1775-1778.
-
Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, Lovell C, Calin A 2001 Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors.
J. Rheumatol. 28: 2667-2673.
-
Brophy S, Taylor G, Blake D, Calin A 2003 The interrelationship between sex, susceptibility factors, and outcome in ankylosing spondylitis and its associated disorders including inflammatory bowel disease, psoriasis, and iritis.
J. Rheumatol. 30: 2054-2058.
-
Brown LM, Gridley G, Check D, Landgren O 2008 Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.
Blood 111: 3388-3394.
*
-
Brown MA 2006 Non-major-histocompatibility-complex genetics of ankylosing spondylitis.
Best Pract. Res. Clin. Rheumatol. 20: 611-621.
-
Brown MA 2008 Breakthroughs in genetic studies of ankylosing spondylitis.
Rheumatology (Oxford) 47: 132-137.
-
Brown MA, Brophy S, Bradbury L, Hamersma J, Timms A, Laval S, Cardon L, Calin A, Wordsworth BP 2003 Identification of major loci controlling clinical manifestations of ankylosing spondylitis.
Arthritis Rheum. 48: 2234-2239.
*
-
Brown MA, Pile KD, Kennedy LG, Campbell D, Andrew L, March R, Shatford JL, Weeks DE, Calin A, Wordsworth BP 1998 A genome-wide screen for susceptibility loci in ankylosing spondylitis.
Arthritis Rheum. 41: 588-595.
*
-
Burgos-Vargas R 1993 Spondyloarthropathies and psoriatic arthritis in children.
Curr. Opin. Rheumatol. 5: 634-643.
-
Butt C, Lim S, Greenwood CM, Rahman P 2007 VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis.
BMC Musculoskelet. Disord. 8: 1.
*
-
Bywaters EG 1983 Historical perspectives in the aetiology of ankylosing spondylitis.
Br. J. Rheumatol. 22 (4 Suppl. 2): 1-4.
-
Calin A 1986 Seronegative spondyloarthritides.
Med. Clin. North Am. 70: 323-336.
-
Calin A, Marder A, Becks E, Burns T 1983 Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls.
Arthritis Rheum. 26: 1460-1464.
-
Caliskan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, Yildirir A, Yucel E, Muderrisoglu H 2008 Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis.
Atherosclerosis 196: 306-312.
-
Callen JP 2007 Complications and adverse reactions in the use of newer biologic agents.
Semin. Cutan. Med. Surg. 26: 6-14.
-
Cameron FH, Russell PJ, Sullivan J, Geczy AF 1983 Is a Klebsiella plasmid involved in the aetiology of ankylosing spondylitis in HLA-B27-positive individuals?
Mol. Immunol. 20: 563-566.
-
Cammelli D 2006 Extra-articular manifestations of seronegative spondyloarthritis.
Recenti Prog. Med. 97: 280-289.
-
Cansu DU, Kalifoglu T, Korkmaz C 2008 Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
J. Rheumatol. 35: 421-424.
-
Caramaschi P, Ruzzenente O, Pieropan S, Volpe A, Carletto A, Bambara LM, Biasi D 2007 Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results.
Rheumatol. Int. 27: 649-654.
*
-
Carter JD, Valeriano J, Vasey FB 2004 Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomized 9-month comparison.
J. Rheumatol. 31: 1973-1980.
-
Carter KW, Pluzhnikov A, Timms AE, Miceli-Richard C, Bourgain C, Wordsworth BP, Jean-Pierre H, Cox NJ, Palmer LJ, Breban M, Reveille JD, Brown MA 2007 Combined analysis of three whole genome linkage scans for ankylosing spondylitis.
Rheumatology (Oxford) 46: 763-771.
*
-
Cascino I, Paladini F, Belfiore F, Cauli A, Angelini C, Fiorillo MT, Mathieu A, Sorrentino R 2007 Identification of previously unrecognized predisposing factors for ankylosing spondylitis from analysis of HLA-B27 extended haplotypes in Sardinia.
Arthritis Rheum. 56: 2640-2651.
*
-
Casellini C, Citera G, Rosemffet M, Ruggeri S, Saviotti A, Cocco JA 2005 Audiovestibular disorders in patients with ankylosing spondylitis.
J. Clin. Rheumatol. 11: 81-85.
-
Cauli A, Dessole G, Fiorillo MT, Vacca A, Mameli A, Bitti P, Passiu G, Sorrentino R, Mathieu A 2002 Increased level of HLA-B27 expression in ankylosing spondylitis patients compared with healthy HLA-B27-positive subjects: a possible further susceptibility factor for the development of disease.
Rheumatology (Oxford) 41: 1375-1379.
*
-
Cauli A, Vacca A, Mameli A, Passiu G, Fiorillo MT, Sorrentino R, Mathieu A 2007 A Sardinian patient with ankylosing spondylitis and HLA-B*2709 co-occurring with HLA-B*1403.
Arthritis Rheum. 56: 2807-2809.
*
-
Cay HF, Gungor HA, Sezer I, Kacar C, Balci N 2006 Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report.
J. Clin. Pharm. Ther. 31: 645-648.
*
-
Charalabopoulos K, Mittari E, Peschos D, Golias C, Charalabopoulos A, Tsanou E, Batistatou A 2006 Rare association of chronic lymphocytic thyroiditis with dermatomyositis.
Arch. Med. Res. 37: 563-565.
-
Chen J, Liu C 2006 Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials.
J. Rheumatol. 33: 722-731.
-
Chen J, Liu C 2005 Sulfasalazine for ankylosing spondylitis.
Cochrane Database Syst. Rev. 2: CD004800.
*
-
Chen J, Liu C 2004 Methotrexate for ankylosing spondylitis.
Cochrane Database Syst. Rev. 3: CD004524.
-
Chen J, Liu C, Lin J 2006 Methotrexate for ankylosing spondylitis.
Cochrane Database Syst. Rev. 4: CD004524.
*
-
Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, Kjer-Nielsen L, Mifsud NA, Tait BD, Holdsworth R, Almeida CA, Nolan D, Macdonald WA, Archbold JK, Kellerher AD, Marriott D, Mallal S, Bharadwaj M, Rossjohn J, McCluskey J 2008 Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.
Immunity 28: 822-832.
*
-
Cheung PP, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj AK, Khoo KB 2008 Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
Intern. Med. J. 38: 396-401.
*
-
Chin G, Luxton G, Harvey JM 2005 Infliximab and nephrotic syndrome.
Nephrol. Dial. Transplant. 20: 2824-2826.
-
Cho J 2000 Update on inflammatory bowel disease genetics.
Curr. Gastroenterol. Rep. 2: 434-439.
-
Choi KH, Lee EB, Yoo CD, Baek HJ, Kang SW, Shin KC, Lee YJ, Kim HA, Jeon JH, Kim CW, Shin DM, Kim IG, Son YW 2005 Clinical significance of anti-filaggrin antibody recognizing uncitrullinated filaggrin in rheumatoid arthritis.
Exp. Mol. Med. 37: 546-552.
*
-
Ciantar M, Adlam DM 2007 Treatment with infliximab: implications in oral surgery? A case report.
Br. J. Oral Maxillofac. Surg. 45: 507-510.
-
Claudepierre P, Wendling D, Cohen JD 2006 Anti-TNF alpha in the treatment of psoriatic arthritis.
Presse. Med. 35: 647-655.
-
Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H 2008 Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.
Rheumatology (Oxford) 47: 897-900.
-
Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P 2007 Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
J. Rheumatol. 34: 380-385.
-
Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M 2008 Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002.
Inflamm. Bowel Dis. 14: 738-743.
*
-
Colbert RA, Deodhar AA, Khan MA, Lories RJ, Maksymowych WP, Reveille JD, Ritchlin CT, Rosenbaum JT, Targan SR, Weisman M, Clegg DO 2008 2007 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN).
J. Rheumatol. 35: 1398-1402.
-
Collantes E, Zarco P, Munoz E, Juanola X, Mulero J, Fernandez-Sueiro JL, Torre-Alonso JC, Gratacos J, Gonzalez C, Batlle E, Fernandez P, Linares LF, Brito E, Carmona L 2007 Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) - extended report.
Rheumatology (Oxford) 46: 1309-1315.
*
-
Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T 1992 Allelic variants of the human putative peptide transporter involved in antigen processing.
Proc. Natl. Acad. Sci. U.S.A. 89: 3932-3936.
*
-
Conti F, Ceccarelli F, Marocchi E, Magrini L, Romana Spinelli F, Spadaro A, Scrivo R, Valesini G 2007 Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Ann. Rheum. Dis. 66: 1393-1397.
-
Correa PA, Tobon GJ, Citera G, Cadena J, Schneeberger E, Camargo JF, Maldonado-Cocco JA, Anaya JM 2004 Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB1.
Biomedica 24: 140-152.
-
Costescu I, Vîlciu A 1998 Clinical observations of a case of anterior uveitis associated with ankylosing spondylitis and psoriatic arthritis. Paraclinical studies.
Oftalmologia 42: 74-77.
-
Crane AM, Bradbury L, van Heel DA, McGovern DP, Brophy S, Rubin L, Siminovitch KA, Wordsworth BP, Calin A, Brown MA 2002 Role of NOD2 variants in spondylarthritis.
Arthritis Rheum. 46: 1629-1633.
*
-
Cravo AR, Tavares V, Canas Da Silva J 2006 Anti-TNF alfa therapy in ankylosing spondylitis.
Acta Med. Port. 19: 141-150.
-
D'Alessandro LP, Forster DJ, Rao NA 1991 Anterior uveitis and hypopyon.
Am. J. Ophthalmol. 112: 317-321.
-
Dagfinrud H, Heiberg MS, Bakland G, Skomsvoll J, Kvien TK 2007 Ankylosing spondylitis - a consensus on diagnosis and treatment.
Tidsskr. Nor. Laegeforen. 127: 3209-3212.
-
Dakwar E, Reddy J, Vale FL, Uribe JS 2008 A review of the pathogenesis of ankylosing spondylitis.
Neurosurg. Focus 24: E2.
-
Darmawan J, Nasution AR, Chen SL, Haq SA, Zhao D, Zeng Q, Davatchi F 2006 Excellent endpoints from step-down bridge combination therapy of 5 immunosuppressants in NSAID-refractory ankylosing spondylitis: 6 year international study in Asia - WHO-ILAR COPCORD Stage II Treatment of the Autoimmune Diseases.
J. Rheumatol. 33: 2484-2492.
-
Dauendorffer JN, Rivet J, Allard A, Bachelez H 2007 Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis.
Br. J. Dermatol. 156: 742-743.
-
Davaine A, Saraux A, Prigent S, Kupfer-Bessaguet I, Roswag D, Plantin P, Schoenlaub P, Talarmin F, Zagnoli A, Misery L 2008 Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study.
J. Eur. Acad. Dermatol. Venereol. Aug 18 [Epub ahead of print].
-
Davis J Jr, Webb A, Lund S, Sack K 2004 Results from an open-label extension study of etanercept in ankylosing spondylitis.
Arthritis Rheum. 51: 302-304.
*
-
Davis JC Jr, Mease PJ 2007 Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic.
Semin. Arthritis Rheum. Dec 29 [Epub ahead of print].
*
-
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group 2003 Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Arthritis Rheum. 48: 3230-3236.
*
-
Davis Jr JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S 2006 The definition of disease duration in ankylosing spondylitis: reassessing the concept.
Ann. Rheum. Dis. 65: 1518-1520.
*
-
De Angelis R, Salaffi F, Grassi W 2007 Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study.
Scand. J. Rheumatol. 36: 14-21.
-
De Keyser F, Baeten D, Van den Bosch F, De Vos M, Cuvelier C, Mielants H, Veys E 2002 Gut inflammation and spondyloarthropathies.
Curr. Rheumatol. Rep. 4: 525-532.
-
De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Verbruggen G, Mielants H, Veys E 2004 Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.
Drugs 64: 2793-2811.
-
de Moura CG, de Moura TG, de Souza SP, Testagrossa L 2006 Inflammatory bowel disease, ankylosing spondylitis, and IgA nephropathy.
J. Clin. Rheumatol. 12: 106-107.
-
de Seny D, Fillet M, Ribbens C, Maree R, Meuwis MA, Lutteri L, Chapelle JP, Wehenkel L, Louis E, Merville MP, Malaise M 2008 Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis.
Clin. Chem. 54: 1066-1075.
*
-
de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M 2000 Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.
J. Rheumatol. 27: 2860-2865.
-
De Vos M 2004 Joint involvement in inflammatory bowel disease.
Aliment. Pharmacol. Ther. 20 Suppl. 4: 36-42.
*
-
de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, Van Denderen JC, Dijkmans BA, Wolbink GJ 2008 Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis (AS).
Ann. Rheum. Dis. Mar 28 [Epub ahead of print].
-
de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE 2007 Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
Ann. Rheum. Dis. 66: 1252-1254.
*
-
Dejaco C, Duftner C, Schirmer M 2008 Imaging techniques for early diagnosis of ankylosing spondylitis.
Wien. Med. Wochenschr. 158: 191-194.
-
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Agenant D, Tytgat GN 1978 Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease.
Ann. Rheum. Dis. 37: 33-35.
*
-
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Meijers KA, Tytgat GN 1978 Ankylosing spondylitis and inflammatory bowel disease. III. Clinical characteristics and results of histocompatibility typing (HLA B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease.
Ann. Rheum. Dis. 37: 36-41.
*
-
Dequeker J, Decock T, Walravens M, Van de Putte I 1978 A systematic survey of the HLA B27 prevalence in inflammatory rheumatic diseases.
J. Rheumatol. 5: 452-459.
-
Desai SB, Furst DE 2006 Problems encountered during anti-tumour necrosis factor therapy.
Best Pract. Res. Clin. Rheumatol. 20: 757-790.
-
Díaz-Pena R, Blanco-Gelaz MA, Suarez-Alvarez B, Martinez-Borra J, Lopez-Vazquez A, Alonso-Arias R, Bruges-Armas J, Vidal-Castineira JR, Lopez-Larrea C 2008 Activating KIR genes are associated with ankylosing spondylitis in Asian populations.
Hum. Immunol. 69: 437-442.
-
Dichamp I, Bourgeois A, Dirand C, Herbein G, Wendling D 2007 Increased nuclear factor-kappaB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-alpha.
J. Rheumatol. 34: 1976-1983.
-
Dincer U, Cakar E, Kiralp MZ, Dursun H 2008 Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria.
Clin. Rheumatol. 27: 457-462.
*
-
Dostal C, Pavelka K, Zvarova J, Hanzlicek P, Olejarova M 2006 Some principles of the development of a clinical database/national register of selected inflammatory rheumatic diseases in the Czech Republic.
Int. J. Med. Inform. 75: 216-223.
-
Dougados M, Hochberg MC 2002 Why is the concept of spondyloarthropathies important?
Best Pract. Res. Clin. Rheumatol. 16: 495-505.
-
Dubey SG, Leeder J, Gaffney K 2008 Physical therapy in anti-TNF treated patients with ankylosing spondylitis.
Rheumatology (Oxford) 47: 1100-1101.
-
Duman I, Balaban B, Tugcu I, Dincer K 2007 Familial mediterranean fever unusually coexisted in an ankylosing spondylitis patient. MEFV mutation has any role?
Rheumatol. Int. 27: 689-690.
*
-
Durand JP, el-Zaatari FA, Krieg AM, Taurog JD 1988 Restriction fragment length polymorphism of T cell receptor alpha and beta chain genes in patients with ankylosing spondylitis.
J. Rheumatol. 15: 1115-1158.
-
Ebner W, Palotai T, Codreanu C, Geher P, Pahor A, Pavelka K, Smolen J, Szechinski J, Zlnay M 2008 Ankylosing spondylitis in Central and Eastern Europe: cross-sectional study on treatment modalities, disease activity and quality of life.
Z. Rheumatol. Aug 20 [Epub ahead of print].
-
Ebringer A, Rashid T 2007 "B27 disease" is a new autoimmune disease that affects millions of people.
Ann. N. Y. Acad. Sci. 1110: 112-120.
-
Ebringer A, Rashid T, Tiwana H, Wilson C 2007 A possible link between Crohn's disease and ankylosing spondylitis via Klebsiella infections.
Clin. Rheumatol. 26: 289-297.
*
-
Edwards CJ 2005 Immunological therapies for rheumatoid arthritis.
Br. Med. Bull. 73-74: 71-82.
*
-
Efthimiou P, Markenson JA 2005 Role of biological agents in immune-mediated inflammatory diseases.
South. Med. J. 98: 192-204.
-
El-Hag K, Dercken HG, Prenzel R, Holzle E 2008 Drug-induced alveolitis associated with infliximab/azathioprine therapy.
Pneumologie. 62: 204-208.
-
Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB 2004 The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
Semin. Arthritis Rheum. 33: 283-288.
*
-
Enlow RW, Bias WB, Arnett FC 1980 The spondylitis of inflammatory bowel disease. Evidence for a non-HLA linked axial arthropathy.
Arthritis Rheum. 23: 1359-1365.
-
Fang M, Chen R, Cai Q, Duan S, Lv K, Cheng N, Sun S 2007 Association of HLA genes with ankylosing spondylitis in Han population of eastern China.
Scand. J. Immunol. 65: 559-566.
*
-
Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P, Williams R, Woody J, Maini RN 2004 Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
Novartis Found. Symp. 256: 53-69.
-
Feldmann M, Pusey CD 2006 Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
J. Am. Soc. Nephrol. 17: 1243-1252.
-
Felizardo M, Gomes A, Sousa M, Teixeira A, Freitas J, Tavares A, Vaz Patto J, Gomes M 2007 Immunosuppression and tuberculosis.
Rev. Port. Pneumol. 13: S23-S24.
-
Feng XG, Ye S, Lu Y, Xu XJ, Gu YY, Shen N, Ye P, Cheng FP, Wang AM, Chen SL 2007 Antikinectin autoantibody in Behcet's disease and several other autoimmune connective tissue diseases.
Clin. Exp. Rheumatol. 25: S80-S85.
-
Ferreiros-Vidal I, Amarelo J, Barros F, Carracedo A, Gomez-Reino JJ, Gonzalez A 2003 Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease.
J. Rheumatol. 30: 102-104.
-
Feuchtenberger M, Kneitz C, Tony HP 2006 Treatment of rheumatoid arthritis (RA) with anticytokines.
MMW Fortschr. Med. 148: 44-45, 47.
-
Fiorillo MT, Greco G, Maragno M, Potolicchio I, Monizio A, Dupuis ML, Sorrentino R 1998 The naturally occurring polymorphism Asp116-->His116, differentiating the ankylosing spondylitis-associated HLA-B*2705 from the non-associated HLA-B*2709 subtype, influences peptide-specific CD8 T cell recognition.
Eur. J. Immunol. 28: 2508-2516.
-
Fiorillo MT, Maragno M, Butler R, Dupuis ML, Sorrentino R 2000 CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis.
J. Clin. Invest. 106: 47-53.
*
-
Fiorillo MT, Ruckert C, Hulsmeyer M, Sorrentino R, Saenger W, Ziegler A, Uchanska-Ziegler B 2005 Allele-dependent similarity between viral and self-peptide presentation by HLA-B27 subtypes.
J. Biol. Chem. 280: 2962-2971.
*
-
Flato B, Hoffmann-Vold AM, Reiff A, Forre O, Lien G, Vinje O 2006 Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study.
Arthritis Rheum. 54: 3573-3582.
*
-
Fleischmann R 2007 Primer: establishing a clinical trial unit - regulations and infrastructure.
Nat. Clin. Pract. Rheumatol. 3: 234-239.
*
-
Fleischmann R, Baumgartner SW, Weisman M, Liu T, White B, Peloso PM 2006 Long-term safety of etanercept in elderly subjects with rheumatic diseases.
Ann. Rheum. Dis. 65: 379-384.
*
-
Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A 2002 Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Drug Saf. 25: 173-197.
-
Fleurence R, Spackman E 2006 Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature.
J. Rheumatol. 33: 2124-2131.
-
Fraile A, Collado MD, Mataran L, Martin J, Nieto A 2000 TAP1 and TAP2 polymorphism in Spanish patients with ankylosing spondylitis.
Exp. Clin. Immunogenet. 17: 199-204.
-
Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis.
Curr. Gastroenterol. Rep. 1: 95-101.
-
Frauendorf E, von Goessel H, May E, Marker-Hermann E 2003 HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides.
Clin. Exp. Immunol. 134: 351-359.
*
-
Freeman HJ, Flak B 2005 Demyelination-like syndrome in Crohn's disease after infliximab therapy.
Can. J. Gastroenterol. 19: 313-316.
-
Freeman HJ, Freeman KJ 2000 Prevalence rates and an evaluation of reported risk factors for osteonecrosis (avascular necrosis) in Crohn's disease.
Can. J. Gastroenterol. 14: 138-143.
-
Freeston J, Barkham N, Hensor E, Emery P, Fraser A 2007 Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies.
Joint Bone Spine 74: 140-143.
-
Freiesleben S, Schou M 2008 Biological treatment of ankylosing spondylitis.
Ugeskr. Laeger. 170: 2140-2145.
-
Fresko I, Ugurlu S, Ozbakir F, Celik A, Yurdakul S, Hamuryudan V, Yazici H 2005 Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behcet's syndrome.
Clin. Exp. Rheumatol. 23: S67-S70.
-
Frigoul A, Lefranc MP 2005 MICA: standardized IMGT allele nomenclature, polymorphisms and diseases.
Recent Res. Devel. Human Genet. 3: 95-145. *
-
Fuchs BS, Hadi S 2006 Use of etanercept in the treatment of psoriasis and psoriatic arthritis.
Rev. Recent Clin. Trials 1: 259-263.
-
Fuchs I, Avnon L, Freud T, Abu-Shakra M 2008 Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors.
Clin. Rheumatol. Sep 16 [Epub ahead of print].
-
Fujita K, Naito S, Okabe N, Yao T 1984 Immunological studies in Crohn's disease. I. Association with HLA systems in the Japanese.
J. Clin. Lab. Immunol. 14: 99-102.
-
Furuichi T, Maeda K, Chou CT, Liu YF, Liu TC, Miyamoto Y, Takahashi A, Mori K, Ikari K, Kamatani N, Kurosawa H, Inoue H, Tsai SF, Ikegawa S 2008 Association of the MSX2 gene polymorphisms with ankylosing spondylitis in Japanese.
J. Hum. Genet. 53: 419-424.
*
-
Galocha B, de Castro JA 2008 Folding of HLA-B27 subtypes is determined by the global effect of polymorphic residues and shows incomplete correspondence to ankylosing spondylitis.
Arthritis Rheum. 58: 401-412.
*
-
Gao P, Lu C, Zhang F, Sang P, Yang D, Li X, Kong H, Yin P, Tian J, Lu X, Lu A, Xu G 2008 Integrated GC-MS and LC-MS plasma metabonomics analysis of ankylosing spondylitis.
Analyst 133: 1214-1220.
*
-
Garg S, Garg K, Altaf M, Magaldi JA 2008 Refractory vertebral sarcoidosis responding to infliximab.
J. Clin. Rheumatol. 14: 238-240.
-
Geczy AF, McGuigan LE, Sullivan JS, Edmonds JP 1986 Cytotoxic T lymphocytes against disease-associated determinant(s) in ankylosing spondylitis.
J. Exp. Med. 164: 932-937.
-
Genc H, Duyur Cakit B, Nacir B, Saracoglu M, Kacar M, Erdem HR 2007 The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases.
Clin. Rheumatol. 26: 1104-1110.
*
-
Gensler L, Davis JC Jr 2006 Recognition and treatment of juvenile-onset spondyloarthritis.
Curr. Opin. Rheumatol. 18: 507-611.
-
Gensler LS, Ward MM, Reveille JD, Learch TC, Weisman MH, Davis JC 2008 Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort.
Ann. Rheum. Dis. 67: 233-237.
-
Gerber N, Ambrosini GC, Boni A, Fehr K, Wagenhauser FJ. 1977 Ankylosing spondylitis (Bechterew) and tissue antigen HLA-B 27. II. HLA-B 27 negativity in classical clinical ankylosing spondylitis: no independent nosological entity.
Z. Rheumatol. 36: 124-129.
-
Gergely Jr P, Blazsek A, Weiszhar Z, Pazar B, Poor G 2006 Lack of genetic association of the Toll-like receptor 4 (TLR4) Asp299Gly and Thr399Ile polymorphisms with spondylarthropathies in a Hungarian population.
Rheumatology (Oxford) 45: 1194-1196.
*
-
Gladman DD 2007 Axial disease in psoriatic arthritis.
Curr. Rheumatol. Rep. 9: 455-460.
-
Glinsky GV 2008 An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway.
Cell Cycle Aug 30 [Epub ahead of print].
*
-
Gobelet C, Luthi F, Al-Khodairy AT, Chamberlain MA 2007 Work in inflammatory and degenerative joint diseases.
Disabil. Rehabil. 29: 1331-1339.
-
Goedecke V, Crane AM, Jaakkola E, Kaluza W, Laiho K, Weeks DE, Wilson J, Kauppi M, Kaarela K, Tuomilehto J, Wordsworth BP, Brown MA 2003 Interleukin 10 polymorphisms in ankylosing spondylitis.
Genes Immun. 4: 74-76.
*
-
Goffe B 2004 Etanercept (Enbrel(R)) - an update.
Skin Therapy Lett. 9: 1-4.
-
Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D 2007 Immune-related disease before and after vasectomy: an epidemiological database study.
Hum. Reprod. 22: 1273-1278.
-
Gomez-Reino JJ, Carmona L; the BIOBADASER Group 2006 Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
Arthritis Res. Ther. 8: R29.
*
-
Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T 2008 Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Clin. Exp. Rheumatol. 26: 401-407.
-
Gonzalez-Lopez L, Sanchez-Hernandez JD, Aguilar-Chavez EA, Cota-Sanchez AR, Lopez-Olivo MA, Villa-Manzano AI, Ortega-Flores R, Espinoza-Magana GL, Rojo-Contreras W, Cardona-Munoz EG, Gamez-Nava JI 2008 Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables.
Rheumatol. Int. 28: 1223-1228.
*
-
Gorman JD, Sack KE, Davis JC Jr 2002 Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
N. Engl. J. Med. 346: 1349-1356.
*
-
Goswami R, Ray D, Sharma R, Tomar N, Gupta R, Gupta N, Sreenivas V 2008 Presence of spondyloarthropathy and its clinical profile in patients with hypoparathyroidism.
Clin. Endocrinol. (Oxf.) 68: 258-263.
*
-
Gran JT, Husby G 1992 Joint manifestations in gastrointestinal diseases. 1. Pathophysiological aspects, ulcerative colitis and Crohn's disease.
Dig. Dis. 10: 274-294.
-
Gravallese EM, Kantrowitz FG 1988 Arthritic manifestations of inflammatory bowel disease.
Am. J. Gastroenterol. 83: 703-709.
-
Grubic Z 2006 HLA-B27 gene: polymorphism, evolution, distribution, and association with spondyloartopathies.
Reumatizam 53: 5-10.
-
Gu MM, Yuan WT, Yang JQ, Zhang J, Xiong XY, Yao FJ, Lu ZY, Wang ZG, Huang W, Fan LA 2004 A genomewide scan for the susceptibility gene loci to ankylosing spondylitis in Chinese Han population.
Yi Chuan Xue Bao 31: 217-220.
-
Gunal EK, Sarvan FO, Kamali S, Gul A, Inanc M, Carin M, Konice M, Aral O, Ocal L 2008 Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey.
Joint Bone Spine 75: 299-302.
-
Haapamaki J, Turunen U, Roine RP, Farkkila MA, Arkkila PE 2008 Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey.
Scand. J. Gastroenterol. 43: 821-830.
*
-
Hahn BH, Grossman J, Chen W, McMahon M 2007 The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia.
J. Autoimmun. 28: 69-75.
-
Hajjaj-Hassouni N, Burgos-Vargas R 2008 Ankylosing spondylitis and reactive arthritis in the developing world.
Best Pract. Res. Clin. Rheumatol. 22: 709-723.
-
Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV 2006 Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and aAnkylosing spondylitis.
J. Rheumatol. 33: 2167-2172.
-
Han C, Smolen J, Kavanaugh A, van der Heijde D, Braun J, Westhovens R, Zhao N, Rahman MU, Baker D, Bala M 2007 The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases.
Arthritis Res. Ther. 9: R103.
*
-
Hanauer SB 2005 A BALANCING VIEW: lifetime channeling of infliximab for Crohn's disease.
Am. J. Gastroenterol. 100: 1438-1439.
*
-
Hanauer SB 2004 Update on the etiology, pathogenesis and diagnosis of ulcerative colitis.
Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 26-31.
*
-
Handa R 2003 Spondylo-arthropathies.
J. Indian Med. Assoc. 101: 514, 516, 518.
-
Hanta I, Ozbek S, Kuleci S, Kocabas A 2008 The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients.
Clin. Rheumatol. 27: 1083-1086.
*
-
Hanta I, Ozbek S, Kuleci S, Sert M, Kocabas A 2007 Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha.
Clin. Rheumatol. 26: 1867-1870.
*
-
Hanzlicek P, Zvarova J, Dostal C 2006 Information technology in clinical research in rheumatology domain.
Stud. Health Technol. Inform. 124: 187-192.
-
Haraoui B 2005 Differentiating the efficacy of tumor necrosis factor inhibitors.
J. Rheumatol. Suppl. 74: 3-7.
-
Haraoui B 2005 Differentiating the efficacy of the tumor necrosis factor inhibitors.
Semin. Arthritis Rheum. 34: 7-11.
*
-
Haraoui B, Keystone E 2006 Musculoskeletal manifestations and autoimmune diseases related to new biologic agents.
Curr. Opin. Rheumatol. 18: 96-100.
-
Haraoui B, Krelenbaum M 2008 Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
Semin. Arthritis Rheum. Aug 12 [Epub ahead of print].
*
-
Harjacek M, Ostojic J, Djakovic Rode O 2006 Juvenile spondyloarthropathies associated with Mycoplasma pneumoniae infection.
Clin. Rheumatol. 25: 470-475.
-
Hawrelak JA, Myers SP 2004 The causes of intestinal dysbiosis: a review.
Altern. Med. Rev. 9: 180-197.
*
-
Healy PJ, Helliwell PS 2008 Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis.
Arthritis Rheum. 59: 686-691.
*
-
Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, Kvien TK 2008 The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Arthritis Rheum. 59: 234-240.
*
-
Helenius LM, Hallikainen D, Helenius I, Meurman JH, Koskimies S, Tervahartiala P, Kivisaari L, Hietanen J, Suuronen R, Lindqvist C, Leirisalo-Repo M 2004 HLA-DRB1* alleles and temporomandibular joint erosion in patients with various rheumatic diseases.
Scand. J. Rheumatol. 33: 24-29.
-
Helenius LM, Meurman JH, Helenius I, Kari K, Hietanen J, Suuronen R, Hallikainen D, Kautiainen H, Leirisalo-Repo M, Lindqvist C 2005 Oral and salivary parameters in patients with rheumatic diseases.
Acta Odontol. Scand. 63: 284-293.
-
Helenius LM, Tervahartiala P, Helenius I, Al-Sukhun J, Kivisaari L, Suuronen R, Kautiainen H, Hallikainen D, Lindqvist C, Leirisalo-Repo M 2006 Clinical, radiographic and MRI findings of the temporomandibular joint in patients with different rheumatic diseases.
Int. J. Oral Maxillofac. Surg. 35: 983-989.
-
Helliwell PS, Taylor WJ 2005 Classification and diagnostic criteria for psoriatic arthritis.
Ann. Rheum. Dis. 64 Suppl. 2: ii3-ii8.
*
-
Henderson C, Davis JC 2006 Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.
Nat. Clin. Pract. Rheumatol. 2: 211-218.
*
-
Herman S, Kronke G, Schett G 2008 Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.
Trends Mol. Med. 14: 245-253.
*
-
Hermann E, Fleischer B, Meyer zum Buschenfelde KH 1994 Bacteria-specific cytotoxic CD8+ T cells: a missing link in the pathogenesis of the HLA-B27-associated spondylarthropathies.
Ann. Med. 26: 365-369.
-
Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B 1993 HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis.
Lancet 342: 646-650.
-
Hetland ML 2005 DANBIO: a nationwide registry of biological therapies in Denmark.
Clin. Exp. Rheumatol. 23: S205-S207.
-
Ho HH, Yu KH, Chen JY, Lin JL, Wu YJ, Luo SF, Liou LB 2007 Coexisting ankylosing spondylitis and gouty arthritis.
Clin. Rheumatol. 26: 1655-1661.
*
-
Ho P, Barton A, Worthington J 2004 Genetic epidemiology of psoriatic arthritis.
Mod. Rheumatol. 14: 91-100.
-
Hollis-Moffatt JE, Merriman ME, Rodger RA, Rowley KA, Chapman PT, Dalbeth N, Gow PJ, Harrison AA, Highton J, Jones PB, O'Donnell JL, Stamp LK, Merriman TR 2008 Evidence for association of an interleukin-23 receptor variant independent of the R381Q variant with rheumatoid arthritis.
Ann. Rheum. Dis. Jul 22 [Epub ahead of print].
-
Homeff G, Burgos-Vargas R 2002 TNF-alpha antagonists for the treatment of juvenile-onset spondyloarthritides.
Clin. Exp. Rheumatol. 20: S137-S142.
-
Horneff G 2005 Treatment of juvenile idiopathic arthritis.
Z. Rheumatol. 64: 317-326.
-
Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S 2004 Gene map of the extended human MHC.
Nat. Rev. Genet. 5: 889-899.
*
-
Hou TY, Chen HC, Chen CH, Chang DM, Liu FC, Lai JH 2007 Usefulness of human leucocyte antigen-B27 subtypes in predicting ankylosing spondylitis: Taiwan experience.
Intern. Med. J. 37: 749-752.
*
-
Howarth PH, Babu KS, Arshad HS, Lau LC, Buckley MG, McConnell W, Beckett P, Ali MA, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST 2005 Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma.
Thorax 60: 1012-1018.
*
-
Howe HS, Zhao L, Song YW, Springer L, Edmonds J, Gu J, Yu DT 2007 Seronegative spondyloarthropathy - studies from the Asia Pacific region.
Ann. Acad. Med. Singapore 36: 135-141.
-
Hoy SM, Scott LJ 2007 Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis.
Drugs 67: 2609-2633.
-
Huang CM, Yang YH, Chiang BL 2004 Different familial association patterns of autoimmune diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid arthritis.
J. Microbiol. Immunol. Infect. 37: 88-94.
*
-
Huang F, Cai XH, Shi GY 1992 Role of enteric Klebsiella pneumonia infection and HLA-B27 in ankylosing spondylitis.
Zhonghua Nei Ke Za Zhi 31: 398-400, 443.
-
Huang J, Li C, Xu H, Gu J 2008 Novel non-HLA-susceptible regions determined by meta-analysis of four genomewide scans for ankylosing spondylitis.
J. Genet. 87: 75-81.
*
-
Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, Van Venrooij WJ, Metzger AL, Genovese MC, Robinson WH 2007 Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline reactivity is associated with upregulation of proinflammatory cytokines.
Ann. Rheum. Dis. 66: 712-719.
*
-
Huerta-Sil G, Casasola-Vargas J, Londono JD, Ruiz-Rivas R, Chavez J, Pacheco-Tena C, Cardiel M, Vargas-Alarcon G, Burgos-Vargas R 2006 Low-grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling ankylosing spondylitis diagnostic criteria throughout follow-up.
Ann. Rheum. Dis. 65: 642-646.
*
-
Hulsmeyer M, Fiorillo MT, Bettosini F, Sorrentino R, Saenger W, Ziegler A, Uchanska-Ziegler B 2004 Dual, HLA-B27 subtype-dependent conformation of a self-peptide.
J. Exp. Med. 199: 271-281.
*
-
Hulsmeyer M, Welfle K, Pohlmann T, Misselwitz R, Alexiev U, Welfle H, Saenger W, Uchanska-Ziegler B, Ziegler A 2005 Thermodynamic and structural equivalence of two HLA-B27 subtypes complexed with a self-peptide.
J. Mol. Biol. 346: 1367-1379.
*
-
Hussein A 1987 HLA-B27 associated spondyloarthritis in childhood.
Monatsschr. Kinderheilkd. 135: 185-194.
-
Hutas G 2008 Golimumab, a fully human monoclonal antibody against TNFalpha.
Curr. Opin. Mol. Ther. 10: 393-406.
-
Hyla JF, Franck WA, Davis JS 1976 Lack of association of HLA B27 with radiographic sacroiliitis in inflammatory bowel disease.
J. Rheumatol. 3: 196-200.
-
Ikeda M, Yu DT 1998 The pathogenesis of HLA-B27 arthritis: role of HLA-B27 in bacterial defense.
Am. J. Med. Sci. 316: 257-263.
-
Inman RD 2006 Mechanisms of disease: infection and spondyloarthritis.
Nat. Clin. Pract. Rheumatol. 2: 163-169.
*
-
Jaakkola E, Crane AM, Laiho K, Herzberg I, Sims AM, Bradbury L, Calin A, Brophy S, Kauppi M, Kaarela K, Wordsworth BP, Tuomilehto J, Brown MA 2004 The effect of transforming growth factor beta1 gene polymorphisms in ankylosing spondylitis.
Rheumatology (Oxford) 43: 32-38.
*
-
Jaakkola E, Herzberg I, Laiho K, Barnardo MC, Pointon JJ, Kauppi M, Kaarela K, Tuomilehto-Wolf E, Tuomilehto J, Wordsworth BP, Brown MA 2006 Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis.
Ann. Rheum. Dis. 65: 775-780.
*
-
Jacobson JA, Girish G, Jiang Y, Resnick D 2008 Radiographic evaluation of arthritis: inflammatory conditions.
Radiology 248: 378-389.
-
James WH 1991 Sex ratios and hormones in HLA related rheumatic diseases.
Ann. Rheum. Dis. 50: 401-404.
*
-
Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P 2008 Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.
Arthritis Rheum. 58: 2307-2317.
*
-
Jara LJ, Silveira LH, Cuellar ML, Pineda CJ, Scopelitis E, Espinoza LR 1994 Hyperprolactinemia in Reiter's syndrome.
J. Rheumatol. 21: 1292-1297.
-
Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Monteiro J, Kern M, Criswell LA, Albani S, Nelson JL, Clegg DO, Pope R, Schroeder HW Jr, Bridges SL Jr, Pisetsky DS, Ward R, Kastner DL, Wilder RL, Pincus T, Callahan LF, Flemming D, Wener MH, et al 2001 A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases.
Am. J. Hum. Genet. 68: 927-936.
*
-
Jiao YL, Ma CY, Wang LC, Cui B, Zhang J, You L, Chen ZJ, Li JF, Zhao YR 2008 Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease.
J. Clin. Immunol. 28: 343-349.
*
-
Jin L, Weisman M, Zhang G, Ward M, Luo J, Bruckel J, Inman R, Khan MA, Schumacher HR, Maksymowych WP, Mahowald M, Martin T, Rosenbaum JT, Yu DT, Stone M, Watson J, Dickman E, Davis J, Reveille JD 2005 Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis suscesptibility and severity.
Rheumatology (Oxford) 44: 55-60.
*
-
Juan A, Ibanez M, Saez de Ibarra JI, Ros I, Cremer D, Rosell J 2008 Dissection of the ascending aorta in a patient with HLA-B27 associated ankylosing spondylitis.
J. Rheumatol. 35: 713-716.
-
Kaijzel EL, Brinkman BM, van Krugten MV, Smith L, Huizinga TW, Verjans GM, Breedveld FC, Verweij CL 1999 Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis.
Hum. Immunol. 60: 140-144.
-
Kalden JR 2002 Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
Arthritis Res. 4 Suppl. 2: S34-S40.
*
-
Kanski JJ 1981 Care of children with anterior uveitis.
Trans. Ophthalmol. Soc. U.K. 101: 387-390.
-
Karban A, Waterman M, Panhuysen CI, Pollak RD, Nesher S, Datta L, Weiss B, Suissa A, Shamir R, Brant SR, Eliakim R 2004 NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic jews with Crohn's disease.
Am. J. Gastroenterol. 99: 1134-1140.
*
-
Karr RW, Hahn Y, Schwartz BD 1982 Structural identity of human histocompatibility leukocyte antigen-B27 molecules from patients with ankylosing spondylitis and normal individuals.
J. Clin. Invest. 69: 443-450.
-
Kary S, Worm M, Audring H, Huscher D, Renelt M, Soerensen H, Staender E, Maass U, Lee HH, Sterry W, Burmester GR 2006 New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving TNF-alpha-antagonists.
Ann. Rheum. Dis. 65: 405-407.
*
-
Kataria RK, Brent LH 2004 Spondyloarthropathies.
Am. Fam. Physician 69: 2853-2860.
*
-
Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR 2004 Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
Am. J. Gastroenterol. 99: 2385-2392.
*
-
Kavanaugh A, Tutuncu Z, Catalan-Sanchez T 2006 Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
Curr. Opin. Rheumatol. 18: 347-353.
-
Kellner H, Yu D 1994 The pathogenesis of HLA-B27 associated arthritis: lessons from the B27 crystal.
Clin. Investig. 72: 321-328.
-
Kettering JM, Towers JD, Rubin DA 1996 The seronegative spondyloarthropathies.
Semin. Roentgenol. 31: 220-228.
-
Khan MA 2002 Update on spondyloarthropathies.
Ann. Intern. Med. 136: 896-907.
*
-
Khan MA, Kellner H 1992 Immunogenetics of spondyloarthropathies.
Rheum. Dis. Clin. North Am. 18: 837-864.
-
Khan MA, Kushner I, Braun WE 1981 Association of HLA-A2 with uveitis in HLA-B27 positive patients with ankylosing spondylitis.
J. Rheumatol. 8: 295-298.
-
Khan MA, Mathieu A, Sorrentino R, Akkoc N 2007 The pathogenetic role of HLA-B27 and its subtypes.
Autoimmun. Rev. 6: 183-189.
*
-
Khanna M, Shirodkar MA, Gottlieb AB 2003 Etanercept therapy in patients with autoimmunity and hepatitis C.
J. Dermatolog. Treat. 14: 229-232.
-
Kim HR, Kim HY, Lee SH 2006 Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
Rheumatology (Oxford) 45: 1197-1200.
*
-
Kim HY, Renshaw-Gegg LW, Balciunas AM, Kohno T 2007 Construction and purification of the murine p75-murine IgG1 fusion protein.
J. Investig. Dermatol. Symp. Proc. 12: 48-49.
-
Kim TH, Kim TJ, Lee HS, Uhm WS, Shin ES, Na YI, Jun JB 2008 Single nucleotide polymorphism of COL6A1 in patients with ankylosing spondylitis.
J. Rheumatol. 35: 1849-1852.
-
Kim TH, Rahman P, Jun JB, Lee HS, Park YW, Im HJ, Snelgrove T, Peddle L, Hallett D, Inman RD 2004 Analysis of CARD15 polymorphisms in Korean patients with ankylosing spondylitis reveals absence of common variants seen in Western populations.
J. Rheumatol. 31: 1959-1961.
-
Kim TH, Stone MA, Rahman P, Yoo DH, Park YW, Payne U, Hallett D, Inman RD 2005 Interleukin 1 and nuclear factor-kB polymorphisms in ankylosing spondylitis in Canada and Korea.
J. Rheumatol. 32: 1907-1910.
-
Kim TH, Uhm WS, Inman RD 2005 Pathogenesis of ankylosing spondylitis and reactive arthritis.
Curr. Opin. Rheumatol. 17: 400-405.
-
Kim TJ, Kim TH, Lee HJ, Peddle L, Rahman P, Hu P, Greenwood CM, Inman RD 2008 Interleukin 1 polymorphisms in patients with ankylosing spondylitis in Korea.
J. Rheumatol. 35: 1603-1608.
-
Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, Comaneshter D, Paran D, Wigler I, Levartovsky D, Berliner S, Elkayam O 2007 Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis.
Semin. Arthritis Rheum. 36: 203-209.
*
-
Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA 2006 Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
J. Rheumatol. 33: 921-923.
-
Klotz U, Teml A, Schwab M 2007 Clinical pharmacokinetics and use of infliximab.
Clin. Pharmacokinet. 46: 645-660.
-
Knox DL 1979 Psoriasis and intraocular inflammation.
Trans. Am. Ophthalmol. Soc. 77: 210-224.
*
-
Kobak S, Oksel F, Kabasakal Y, Doganavsargil E 2007 Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients.
Clin. Rheumatol. 26: 2191-2194.
-
Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J 2004 The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R)).
Rheumatology (Oxford) 43: 1158-1166.
*
-
Kochbati S, Ben Miled M, Boussema F, Ketari S, Ben Maatallah Kochbati A, Kraiem S, Ben Amor G, Ben Rhouma S, Cherif O, Rokbani L 2004 Cardiac involvement in spondylarthropathies.
Tunis. Med. 82: 1082-1090.
-
Kolarz B, Targonska-Stepniak B, Darmochwal-Kolarz D, Majdan M 2007 Autoimmune aspects of treatment with TNF-alpha inhibitors.
Postepy Hig. Med. Dosw. (Online) 61: 478-484.
-
Konno Y, Numaga J, Mochizuki M, Mitsui H, Hirata R, Maeda H 1998 TAP polymorphism is not associated with ankylosing spondylitis and complications with acute anterior uveitis in HLA-B27-positive Japanese.
Tissue Antigens 52: 478-483.
-
Korkmaz C 2006 Delayed diagnosis of porphyria based on manifestations of systemic lupus erythematosus and ankylosing spondylitis.
J. Nephrol. 19: 535-539.
-
Kubota D, Kanai T, Matsumoto T, Kawamura T, Itsui Y, Okada E, Chin S, Ohoka S, Tsuchiya K, Araki A, Sakamoto N, Miyata T, Watanabe M 2006 A case of sacroiliitis complicated by ulcerative colitis that was successfully treated with steroid.
Nippon Shokakibyo Gakkai Zasshi 103: 936-942.
-
Kuisma J, Jarvinen H, Kahri A, Farkkila M 2004 Factors associated with disease activity of pouchitis after surgery for ulcerative colitis.
Scand. J. Gastroenterol. 39: 544-548.
*
-
Kumar A, Bansal M, Srivastava DN, Pandhi A, Menon A, Mehra NK, Malaviya AN 2001 Long-term outcome of undifferentiated spondylarthropathy.
Rheumatol. Int. 20: 221-224.
*
-
Kuon W, Holzhutter HG, Appel H, Grolms M, Kollnberger S, Traeder A, Henklein P, Weiss E, Thiel A, Lauster R, Bowness P, Radbruch A, Kloetzel PM, Sieper J 2001 Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases.
J. Immunol. 167: 4738-4746.
*
-
Kuon W, Kuhne M, Busch DH, Atagunduz P, Seipel M, Wu P, Morawietz L, Fernahl G, Appel H, Weiss EH, Krenn V, Sieper J 2004 Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthropathy.
J. Immunol. 173: 4859-4866.
*
-
Kvien TK, Moller P, Dale K 1985 Juvenile ankylosing spondylitis and HLA B27 homozygosity.
Scand. J. Rheumatol. 14: 47-50.
-
Laasila K, Leirisalo-Repo M 1994 Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease.
Scand. J. Rheumatol. 23: 338-340.
-
Lamarque D, Nhieu JT, Breban M, Bernardeau C, Martin-Garcia N, Szepes Z, Delchier JC, Whittle B, Claudepierre P 2003 Lymphocytic infiltration and expression of inducible nitric oxide synthase in human duodenal and colonic mucosa is a characteristic feature of ankylosing spondylitis.
J. Rheumatol. 30: 2428-2436.
-
Lambert JR, Wright V 1976 Eye inflammation in psoriatic arthritis.
Ann. Rheum. Dis. 35: 354-356.
*
-
Landewe R, Rump B, Van Der Heijde D, Van Der Linden S 2004 Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists.
Ann. Rheum. Dis. 63: 530-534.
*
-
Langer HE 2008 Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis.
Wien. Med. Wochenschr. 158: 200-205.
-
Lanna CC, Ferrari MD, Rocha SL, Nascimento E, de Carvalho MA, da Cunha AS 2008 A cross-sectional study of 130 Brazilian patients with Crohn's disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations.
Clin. Rheumatol. 27: 503-509.
*
-
Lashner BA 2003 Clinical advances in ulcerative colitis.
American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland.
-
Laval SH, Timms A, Edwards S, Bradbury L, Brophy S, Milicic A, Rubin L, Siminovitch KA, Weeks DE, Calin A, Wordsworth BP, Brown MA 2001 Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci.
Am. J. Hum. Genet. 68: 918-926.
*
-
Le GT, Abbenante G 2005 Inhibitors of TACE and caspase-1 as anti-inflammatory drugs.
Curr. Med. Chem. 12: 2963-2977.
-
Lebwohl MG 2005 Use of etanercept in the dermatology setting: a review.
Am. J. Clin. Dermatol. 6: 49-59.
-
Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA 2008 Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.
Br. J. Dermatol. Jul 4 [Epub ahead of print].
*
-
Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G 2006 Henoch-Schonlein purpura after etanercept therapy for psoriasis.
J. Clin. Rheumatol. 12: 249-251.
-
Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M 2007 Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
Br. J. Dermatol. 156: 486-491.
*
-
Lee JY, Chang HK, Kim SK 2008 Successful etanercept therapy for refractory sacroiliitis in a patient with ankylosing spondylitis and mixed connective tissue disease.
Yonsei Med. J. 49: 159-162.
*
-
Lee SH, Lee YA, Woo DH, Song R, Park EK, Ryu MH, Kim YH, Kim KS, Hong SJ, Yoo MC, Yang HI 2006 Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population.
Arthritis Res. Ther. 8: R163.
*
-
Lee W, Reveille JD, Davis JC Jr, Learch TJ, Ward MM, Weisman MH 2007 Are there gender differences in the severity of ankylosing spondylitis: results from the PSOAS cohort.
Ann. Rheum. Dis. 66: 633-638.
*
-
Lee YH, Rho YH, Choi SJ, Ji JD, Song GG 2005 Ankylosing spondylitis susceptibility loci defined by genome-search meta-analysis.
J. Hum. Genet. 50: 453-459.
*
-
Leistner K, Wessel G 1982 Epidemiologic aspects of seronegative spondylarthritis.
Z. Gesamte. Inn. Med. 37: 627-632.
-
Lemin AJ, Saleki K, van Lith M, Benham AM 2007 Activation of the unfolded protein response and alternative splicing of ATF6alpha in HLA-B27 positive lymphocytes.
FEBS Lett. 581: 1819-1824.
*
-
Leong RW, Lau JY, Sung JJ 2004 The epidemiology and phenotype of Crohn's disease in the Chinese population.
Inflamm. Bowel Dis. 10: 646-651.
*
-
Leung YY, Tam LS, Kun EW, Ho KW, Li EK 2008 Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses.
J. Rheumatol. 35: 1613-1621.
-
Li KJ, Yu CL, Hsu CY, Hsieh SC, Hsu PN 2006 Spinal pseudoarthrosis: a rare complication in psoriatic arthritis.
J. Formos. Med. Assoc. 105: 685-688.
-
Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY 2008 Clinical study of etanercept for treating ankylosing spondylitis.
Nan Fang Yi Ke Da Xue Xue Bao 28: 1349-1351.
-
Liao CH, Huang JL 2003 Juvenile ankylosing spondylitis with uveitis.
Asian Pac. J. Allergy Immunol. 21: 69-71.
-
Liao HT, Chen HA, Chen CH, Wang HP, Tsai CY, Chang HN, Chou CT 2006 Undifferentiated spondyloarthropathy in Chinese patients.
Arch. Med. Res. 37: 384-387.
-
Liao HT, Lin KC, Chen CH, Liang TH, Lin MW, Tsai CY, Tak Yan Yu D, Chou CT 2007 Human leukocyte antigens in undifferentiated spondyloarthritis.
Semin. Arthritis Rheum. 37: 198-201.
-
Lim LL, Fraunfelder FW, Rosenbaum JT 2007 Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
Arthritis Rheum. 56: 3248-3252.
*
-
Linder R, Hoffmann A, Brunner R 2004 Prevalence of the spondyloarthritides in patients with uveitis.
J. Rheumatol. 31: 2226-2229.
-
Lindsley CB, Schaller JG 1974 Arthritis associated with inflammatory bowel disease in children.
J. Pediatr. 84: 16-20.
-
Linssen A, Dekker-Saeys AJ, Dijkstra PF, Rothova A, Kruit PJ, Bakker M, Kijlstra A, Feltkamp TE 1986 The use of HLA-B27 as a diagnostic and prognostic aid in acute anterior uveitis (AAU) in The Netherlands.
Doc. Ophthalmol. 64: 217-223.
-
Linssen A, Meenken C 1995 Outcomes of HLA-B27-positive and HLA-B27-negative acute anterior uveitis.
Am. J. Ophthalmol. 120: 351-361.
-
Liu B, Guo CY, Liu WQ, Wu N, Xing Q 2005 The value of erythrocyte sedimentation rate and C-reactive protein in evaluating disease activity in ankylosing spondylitis.
Zhonghua Nei Ke Za Zhi 44: 566-569.
-
Loos T, Dekeyzer L, Struyf S, Schutyser E, Gijsbers K, Gouwy M, Fraeyman A, Put W, Ronsse I, Grillet B, Opdenakker G, Damme JV, Proost P 2006 TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis.
Lab. Invest. 86: 902-916.
*
-
Lopez D, Garcia-Hoyo R, Garcia F, Lopez de Castro JA 1994 T cell allorecognition and endogenous HLA-B27-bound peptides in a cell line with defective HLA-B27-restricted antigen presentation.
Eur. J. Immunol. 24: 1194-1199.
-
Lopez de Castro JA 2007 HLA-B27 and the pathogenesis of spondyloarthropathies.
Immunol. Lett. 108: 27-33.
-
Lopez-Larrea C, Gonzalez S, Martinez-Borra J 1998 The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy.
Mol. Med. Today 4: 540-549.
-
Lopez-Larrea C, Gonzalez-Roces S, Alvarez V 1996 HLA-B27 structure, function, and disease association.
Curr. Opin. Rheumatol. 8: 296-308.
-
Lories RJ 2006 Animal models of spondyloarthritis.
Curr. Opin. Rheumatol. 18: 342-346.
-
Lou YJ, Jin J, Mai WY 2007 Ankylosing spondylitis presenting with macrophage activation syndrome.
Clin. Rheumatol. 26: 1929-1930.
*
-
Lu MC, Yang KL, Tung CH, Huang KY, Yu HC, Liu SQ, Lai NS 2008 Higher LPS-stimulated TNF-alpha mRNA levels in peripheral blood mononuclear cells from Chinese ankylosing spondylitis patients with -308(G/A) polymorphism in promoter region of tumor necrosis factor: association with distinct A33/B58/Cw10 haplotypes.
Rheumatol. Int. Aug 22 [Epub ahead of print].
*
-
Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D 2008 Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
Ann. Rheum. Dis. Jul 14 [Epub ahead of print].
-
Luukkainen RK, Virtanen KO, Kaarela K 2007 Occurrence of sacroiliitis in patients with seronegative oligoarthritis.
Clin. Rheumatol. 26: 715-717.
*
-
Macewan DJ 2008 Interactions between TNF and GnRH.
Neurochem. Res. 33: 678-682.
-
Maksymowych WP 2007 Update on the treatment of ankylosing spondylitis.
Ther. Clin. Risk Manag. 3: 1125-1133.
-
Maksymowych WP, Gorodezky C, Olivo A, Alaez C, Wong C, Burgos-Vargas R, Sanchez-Corona J, Ramos-Remus C, Russell AS 1997 HLA-DRB1*08 influences the development of disease in Mexican Mestizo with spondyloarthropathy.
J. Rheumatol. 24: 904-907.
-
Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, van der Heijde D 2007 Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis.
Arthritis Rheum. 56: 1846-1853.
*
-
Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis J Jr 2005 Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
J. Rheumatol. 32: 1911-1917.
-
Maksymowych WP, Rahman P, Reeve JP, Gladman DD, Peddle L, Inman RD 2006 Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations.
Arthritis Rheum. 54: 974-985.
*
-
Maksymowych WP, Reeve JP, Reveille JD, Akey JM, Buenviaje H, O'Brien L, Peloso PM, Thomson GT, Jin L, Russell AS 2003 High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry.
Arthritis Rheum. 48: 2011-2018.
*
-
Maksymowych WP, Suarez-Almazor M, Chou CT, Russell AS 1995 Polymorphism in the LMP2 gene influences susceptibility to extraspinal disease in HLA-B27 positive individuals with ankylosing spondylitis.
Ann. Rheum. Dis. 54: 321-324.
-
Maksymowych WP, Tao S, Vaile J, Suarez-Almazor M, Ramos-Remus C, Russell AS 2000 LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis.
J. Rheumatol. 27: 183-189.
-
Mallas EG, Mackintosh P, Asquith P, Cooke WT 1976 Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27).
Gut 17: 906-910.
*
-
Manadan AM, James N, Block JA 2007 New therapeutic approaches for spondyloarthritis.
Curr. Opin. Rheumatol. 19: 259-264.
-
Manguso F, Sanges M, Staiano T, Gargiulo S, Nastro P, Gargano D, Somma P, Mansueto G, Peluso R, Scarpa R, D'Armiento FP, Astarita C, Ayala F, Renda A, Mazzacca G, D'Arienzo A 2004 Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis.
Am. J. Gastroenterol. 99: 327-334.
*
-
Mansour M, Cheema GS, Naguwa SM, Greenspan A, Borchers AT, Keen CL, Gershwin ME 2007 Ankylosing spondylitis: a contemporary perspective on diagnosis and treatment.
Semin. Arthritis Rheum. 36: 210-223.
*
-
Marcilla M, Lopez de Castro JA 2008 Peptides: the cornerstone of HLA-B27 biology and pathogenetic role in spondyloarthritis.
Tissue Antigens 71: 495-506.
*
-
Marcora S, Casanova F, Williams E, Jones J, Elamanchi R, Lemmey A 2006 Preliminary evidence for cachexia in patients with well-established ankylosing spondylitis.
Rheumatology (Oxford) 45: 1385-1388.
*
-
Marker-Hermann E 2008 Early spondyloarthritis.
Internist (Berl.) 49: 271-277.
-
Marks DJ, Mitchison NA, Segal AW, Sieper J 2006 Can unresolved infection precipitate autoimmune disease?
Curr. Top. Microbiol. Immunol. 305: 105-125.
-
Marti M, Alvarez I, Lopez de Castro JA 1999 A molecular insight on the association of HLA-B27 with spondyloarthropathies.
Curr. Rheumatol. Rep. 1: 78-85.
-
Martin TM, Zhang G, Luo J, Jin L, Doyle TM, Rajska BM, Coffman JE, Smith JR, Becker MD, Mackensen F, Khan MA, Levinson RD, Schumacher HR, Wade NK, Rosenbaum JT, Reveille JD 2005 A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease.
Arthritis Rheum. 52: 269-274.
*
-
Martinez B, Caraballo L, Hernandez M, Valle R, Avila M, Iglesias Gamarra A 1999 HLA-B27 subtypes in patients with ankylosing spondylitis (As) in Colombia.
Rev. Invest. Clin. 51: 221-226.
-
Martinez-Borra J, Gonzalez S, Lopez-Vazquez A, Gelaz MA, Armas JB, Kanga U, Mehra NK, Lopez-Larrea C 2000 HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility.
Hum. Immunol. 61: 131-139.
-
Marzano A, Ramoni S, Del Papa N, Barbareschi M, Alessi E 2008 Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions.
Lupus 17: 329-331.
-
Masi AT, Medsger TA Jr 1979 A new look at the epidemiology of ankylosing spondylitis and related syndromes.
Clin. Orthop. Relat. Res. 143: 15-29.
-
Mathieu A, Cauli A, Fiorillo MT, Sorrentino R 2008 HLA-B27 and ankylosing spondylitis geographic distribution versus malaria endemic: casual or causal liaison?
Ann. Rheum. Dis. 67: 138-140.
-
Mathieu A, Cauli A, Fiorillo MT, Sorrentino R 2008 HLA-B27 and ankylosing spondylitis geographic distribution as the result of a genetic selection induced by malaria endemic? A review supporting the hypothesis.
Autoimmun. Rev. 7: 398-403.
-
Mau W, Beyer W, Ehlebracht-Konig I, Engel M, Genth E, Greitemann B, Jackel WH, Zink A 2008 Burden of illness: first routine report on socio-medical consequences of inflammatory rheumatic disease in Germany.
Z. Rheumatol. 67: 157-164.
-
Mauro-Filho Gde L, Ribeiro S 1985 Articular manifestations of inflammatory bowel disease.
Arq. Gastroenterol. 22: 186-191.
-
McClusky OE, Lordon RE, Arnett FC Jr 1984 HL-A 27 in Reiter's syndrome and psoriatic arthritis: a genetic factor in disease susceptibility and expression.
J. Rheumatol. 11: 571.
-
McGarry F, Walker R, Sturrock R, Field M 1999 The -308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27.
J. Rheumatol. 26: 1110-1116.
-
McGonagle D, Savic S, McDermott MF 2007 The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self.
Semin. Immunopathol. 29: 303-313.
*
-
McGuigan LE, Geczy AF, Prendergast JK, Edmonds JP, Hart HH, Bashir HV 1986 HLA-B27 associated cross-reactive marker on the cells of New Zealand patients with ankylosing spondylitis.
Ann. Rheum. Dis. 45: 144-148.
-
McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T 2007 Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
Health Technol. Assess. 11: 1-158.
-
Mease PJ 2007 Adalimumab in the treatment of arthritis.
Ther. Clin. Risk Manag. 3: 133-148.
*
-
Mease PJ 2008 Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions.
Semin. Arthritis Rheum. Feb 25 [Epub ahead of print].
*
-
Mease PJ, Antoni CE, Gladman DD, Taylor WJ 2005 Psoriatic arthritis assessment tools in clinical trials.
Ann. Rheum. Dis. 64 Suppl. 2: ii49-ii54.
*
-
Mease PJ, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, Keystone E, Furst DE, Anklesaria P, Heald AE 2008 Local delivery of a recombinant adeno-associated vector containing a tumor necrosis factor-alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
Ann. Rheum. Dis. Aug 4 [Epub ahead of print].
-
Menon KVN, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, Shah V 2004 A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis.
Am. J. Gastroenterol. 99: 255-260.
*
-
Merino E, Montserrat V, Paradela A, Lopez de Castro JA 2005 Two HLA-B14 subtypes (B-1402 and B-1403) differentially associated with ankylosing spondylitis differ substantially in peptide specificity, but have limited peptide and T-cell epitope sharing with HLA-B27.
J. Biol. Chem. 280: 35868-35880.
*
-
Michels H, Greiner K, Heinz C, Horneff G, Ganser G 2007 Other rheumatic diseases with uveitis besides juvenile idiopathic arthritis.
Klin. Monatsbl. Augenheilkd. 224: 473-476.
-
Mielants H, Veys EM, Cuvelier C, De Vos M 1996 Course of gut inflammation in spondylarthropathies and therapeutic consequences.
Baillieres Clin. Rheumatol. 10: 147-164.
-
Mielants H, Veys EM, Cuvelier C, De Vos M 1984 Macroscopic and histological changes of the ileum HLA-B27 related diseases: therapeutic consequences.
Int. J. Clin. Pharmacol. Res. 4: 409-414.
-
Mielants H, Veys EM, Cuvelier C, De Vos M, Botelberghe L 1985 HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis.
J. Rheumatol. 12: 294-298.
-
Mijiyawa M, Oniankitan O, Khan MA 2000 Spondyloarthropathies in sub-Saharan Africa.
Curr. Opin. Rheumatol. 12: 281-286.
-
Milicic A, Lindheimer F, Laval S, Rudwaleit M, Ackerman H, Wordsworth P, Hohler T, Brown MA 2000 Interethnic studies of TNF polymorphisms confirm the likely presence of a second MHC susceptibility locus in ankylosing spondylitis.
Genes Immun. 1: 418-422.
*
-
Miller MM 1984 Ankylosing spondylitis, Reiter's syndrome, psoriatic arthritis, and arthritis of inflammatory bowel disease.
Prim. Care 11: 271-282.
-
Moll JM 1983 Pathogenetic mechanisms in B27 associated diseases.
Br. J. Rheumatol. 22: S93-S103.
-
Moll JM 2007 "The Leeds idea": an historical account of the spondarthritis concept.
Reumatismo 59 Suppl. 1: 13-18.
*
-
Moll JM, Haslock I, Macrae IF, Wright V 1974 Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome.
Medicine (Baltimore) 53: 343-364.
-
Moller P 1987 Seronegative arthritis - etiology and diagnosis.
Scand. J. Rheumatol. Suppl. 66: 119-127.
-
Moller P 1987 Genetics of ankylosing spondylitis, psoriatic arthritis and Reiter's syndrome.
Clin. Exp. Rheumatol. 5 Suppl. 1: S35-S40.
-
Moller P, Vinje O, Berg K 1982 HLA antigens, psoriasis and acute anterior uveitis in Bechterew's syndrome (ankylosing spondylitis).
Clin. Genet. 21: 215-221.
-
Moller P, Vinje O, Fryjordet A 1980 HLA antigens and sacro-iliitis in chronic prostatitis.
Scand. J. Rheumatol. 9: 138-140.
-
Molta CT, Khan MA, Aponte CJ, Reynolds TL, Macintyre SS 1989 Familial occurrence of systemic sclerosis, rheumatoid arthritis and other immunological disorders: report of two kindreds with study of HLA antigens and review of the literature.
Clin. Exp. Rheumatol. 7: 229-236.
-
Monnet D, Moachon L, Dougados M, Brezin AP 2006 Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis.
Nat. Clin. Pract. Rheumatol. 2: 393-397.
*
-
Monowarul Islam SM, Numaga J, Fujino Y, Masuda K, Ohda H, Hirata R, Maeda H, Mitsui H 1995 HLA-DR8 and acute anterior uveitis in ankylosing spondylitis.
Arthritis Rheum. 38: 547-550.
-
Montserrat V, Galocha B, Marcilla M, Vazquez M, Lopez de Castro JA 2006 HLA-B*2704, an allotype associated with ankylosing spondylitis, is critically dependent on transporter associated with antigen processing and relatively independent of tapasin and immunoproteasome for maturation, surface expression, and T cell …
J. Immunol. 177: 7015-7023.
*
-
Mossner R, Thaci D, Mohr J, Patzold S, Bertsch HP, Kruger U, Reich K 2008 Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases.
Arch. Dermatol. Res. 300: 101-105.
*
-
Na KS, Kim TH, Rahman P, Peddle L, Choi CB, Inman RD 2008 Analysis of single nucleotide polymorphisms in Toll-like receptor 4 shows no association with ankylosing spondylitis in a Korean population.
Rheumatol. Int. 28: 627-630.
*
-
Narzi D, Winkler K, Saidowsky J, Misselwitz R, Ziegler A, Bockmann RA, Alexiev U 2008 Molecular determinants of major histocompatibility complex class I complex stability: shaping antigenic features through short- and long-range electrostatic interactions.
J. Biol. Chem. 283: 23093-23103.
*
-
Nash P 2006 Therapies for axial disease in psoriatic arthritis. A systematic review.
J. Rheumatol. 33: 1431-1434.
-
Nash PT, Florin TH 2005 Tumour necrosis factor inhibitors.
Med. J. Aust. 183: 205-208.
*
-
Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE, Reynolds P, Hardy M, King E, Masters J, Hulme J, Maier LM, Smyth D, Bailey R, Cooper JD, Ribas G, Campbell RD, Clayton DG, Todd JA; The Wellcome Trust Case Control Consortium 2007 Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A.
Nature 450: 887-892.
*
-
Newton SM, Mackie SL, Martineau AR, Wilkinson KA, Kampmann B, Fisher C, Dutta S, Levin M, Wilkinson RJ, Pasvol G 2008 Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients.
Clin. Vaccine Immunol. 15: 506-512.
*
-
Nickerson CL, Luthra HS, David CS 1990 Role of enterobacteria and HLA-B27 in spondyloarthropathies: studies with transgenic mice.
Ann. Rheum. Dis. 49: 426-433.
-
Nicknam MH, Mahmoudi M, Amirzargar AA, Ganjalikhani Hakemi M, Khosravi F, Jamshidi AR, Amirkhani A, Ansaripour B, Pourpak Z, Moin M, Nikbin B 2008 Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis.
Iran. J. Allergy Asthma Immunol. 7: 19-24.
-
Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA 2005 Infliximab therapy in ankylosing spondylitis: an observational study.
Ann. Rheum. Dis. 64: 940-942.
*
-
Nikolaisen C, Rekvig OP, Nossent HC 2007 Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis.
Scand. J. Rheumatol. 36: 97-100.
-
Nunez C, Dema B, Cenit MC, Polanco I, Maluenda C, Arroyo R, de Las Heras V, Bartolome M, de la Concha EG, Urcelay E, Martinez A 2008 IL23R: a susceptibility locus for celiac disease and multiple sclerosis?
Genes Immun. 9: 289-293.
*
-
O'Shea FD, Boyle E, Riarh R, Tse SM, Laxer RM, Inman RD 2008 Comparison of clinical and radiographic severity of juvenile-onset versus adult-onset ankylosing spondylitis.
Ann. Rheum. Dis. Sep 9 [Epub ahead of print].
-
O'Shea FD, Tsui FW, Chiu B, Tsui HW, Yazdanpanah M, Inman RD 2007 Retinol (vitamin A) and retinol-binding protein levels are decreased in ankylosing spondylitis: clinical and genetic analysis.
J. Rheumatol. 34: 2457-2459.
-
Olivieri I, Barozzi L, Padula A, De Matteis M, Pavlica P 1998 Clinical manifestations of seronegative spondylarthropathies.
Eur. J. Radiol. 27 Suppl. 1: S3-S6.
-
Olivieri I, D'Angelo S, Cutro MS, Padula A, Peruz G, Montaruli M, Scarano E, Giasi V, Palazzi C, Khan MA 2007 Diffuse idiopathic skeletal hyperostosis may give the typical postural abnormalities of advanced ankylosing spondylitis.
Rheumatology (Oxford) 46: 1709-1711.
-
Olivieri I, D'Angelo S, Scarano E, Santospirito V, Padula A 2007 The HLA-B*2709 subtype in a woman with early ankylosing spondylitis.
Arthritis Rheum. 56: 2805-2807.
*
-
Olivieri I, Scarano E, Padula A, D'Angelo S 2007 Imaging of psoriatic arthritis.
Reumatismo 59 Suppl. 1: 73-76.
*
-
Onal S, Kazokoglu H, Incili B, Demiralp EE, Yavuz S 2006 Prevalence and levels of serum antibodies to gram negative microorganisms in Turkish patients with HLA-B27 positive acute anterior uveitis and controls.
Ocul. Immunol. Inflamm. 14: 293-299.
-
Oniankitan O, Ranaivo N, Carton L, Chevalier X, Claudepierre P 2005 Poorly and well controlled spondyloarthropathies: a comparison of 2 groups of patients.
J. Rheumatol. 32: 77-79.
-
Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP 2000 Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease.
Gastroenterology 118: 274-278.
*
-
Ornetti P, Chevillotte H, Zerrak A, Maillefert JF 2006 Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients.
Drugs Aging 23: 855-860.
-
Orozco G, Garcia-Porrua C, Lopez-Nevot MA, Raya E, Gonzalez-Gay MA, Martin J 2006 Lack of association between ankylosing spondylitis and a functional polymorphism of PTPN22 proposed as a general susceptibility marker for autoimmunity.
Ann. Rheum. Dis. 65: 687-688.
*
-
Ostensen M, Foerger F, Nelson JL, Schumacher A, Hebisch G, Villiger PM 2005 Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum.
Ann. Rheum. Dis. 64: 839-844.
*
-
Ozdil S, Demir K, Boztas G, Danalioglu A, Karaca C, Akyuz F, Aksoy N, Kaymakoglu S, Mungan Z, Besisik F, Cakaloglu Y, Okten A 2003 Crohn's disease; analysis of 105 patients.
Hepatogastroenterology 50 Suppl. 2: cclxxxvii-ccxci.
-
Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C 2007 Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis.
Med. J. Aust. 187: 524-526.
-
Ozsoyler I, Yilik L, Bozok S, Ozbek C, Gurbuz A 2005 Cardiovascular involvement in Crohn's disease in the absence of ankylosing spondylitis.
Heart Vessels 20: 164-166.
*
-
Paladini F, Cocco E, Cauli A, Cascino I, Vacca A, Belfiore F, Fiorillo MT, Mathieu A, Sorrentino R 2008 A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B (*)2705 in Sardinia.
Genes Immun. Jul 31 [Epub ahead of print].
-
Palm O, Moum B, Ongre A, Gran JT 2002 Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study).
J. Rheumatol. 29: 511-515.
-
Pamuk ON, Yesil Y, Donmez S, Unlu E, Koker IH, Cakir N 2008 The results of purified protein derivative test in ankylosing spondylitis patients: clinical features, HRCT results and relationship with TNF-blocker usage.
Rheumatol. Int. Aug 6 [Epub ahead of print].
*
-
Papadimitraki ED, Kyrmizakis DE, Kritikos I, Boumpas DT 2004 Ear-nose-throat manifestations of autoimmune rheumatic diseases.
Clin. Exp. Rheumatol. 22: 485-494.
-
Papp KA, Keystone EC, Shear NH 2007 Mechanism of action, pharmacokinetics, and drug interactions of etanercept in dermatology.
J. Cutan. Med. Surg. 11 Suppl. 1: S3-S13.
-
Paredes J, Barrachina M, Roman J, Moreno-Osset E 2005 Joint disease in inflammatory bowel disease.
Gastroenterol. Hepatol. 28: 240-249.
-
Park KS, Kang SY, Lee WI 2008 HLA-B27 subtypes in Korean patients with ankylosing spondylitis.
Korean J. Lab. Med. 28: 46-52.
-
Park MC, Jung SJ, Park YB, Lee SK 2008 Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Scand. J. Rheumatol. 37: 173-178.
-
Pascher A, Klupp J 2005 Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors?
BioDrugs 19: 211-231.
-
Pavy S, Allanore Y, Kahan A 2005 Spondylarthropathies and anti-TNFalpha drugs.
Rev. Med. Interne. 26: 717-724.
-
Pedersen OB, Svendsen AJ, Ejstrup L, Skytthe A, Harris JR, Junker P 2008 Ankylosing spondylitis in Danish and Norwegian twins: occurrence and the relative importance of genetic vs. environmental effectors in disease causation.
Scand. J. Rheumatol. 37: 120-126.
-
Peeters H, Vander Cruyssen B, Laukens D, Coucke P, Marichal D, Van Den Berghe M, Cuvelier C, Remaut E, Mielants H, De Keyser F, Vos MD 2004 Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease.
Ann. Rheum. Dis. 63: 1131-1134.
*
-
Peeters H, Vander Cruyssen B, Mielants H, de Vlam K, Vermeire S, Louis E, Rutgeerts P, Belaiche J, De Vos M 2008 Clinical and genetic factors associated with sacroiliitis in Crohn's disease.
J. Gastroenterol. Hepatol. 23: 132-137.
*
-
Peixoto MJ, Gonzales T, Spinola H, Couto AR, Gantes Mora M, Brehm A, Santos MR, Garrett F, Bruges Armas J 2005 HLA-B27 polymorphism and spondyloarthropathies.
Acta Med. Port. 18: 283-294.
-
Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N 2008 Alopecia areata universalis elicited during treatment with adalimumab.
Dermatology 216: 320-323.
-
Peloso PM, Braun J 2004 Expanding the armamentarium for the spondyloarthropathies.
Arthritis Res. Ther. 6 Suppl. 2: S36-S43.
*
-
Peretz A 2007 Inflammatory low back pain.
Rev. Med. Brux. 28: 290-293.
-
Peric P, Curkovic B, Potocki K, Babic-Naglic D, Peric S, Cerovski B, Kehler T, Vidovic T 2007 Coexistence of ochronosis and B27 positive ankylosing spondylitis.
Coll. Antropol. 31: 637-640.
-
Peters KM 2007 Non-infective inflammations of the vertebral spine.
Z. Orthop. Ihre. Grenzgeb. 145: R1-R24.
-
Petty RE 1990 Ocular complications of rheumatic diseases of childhood.
Clin. Orthop. Relat. Res. 259: 51-59.
-
Petty RE, Malleson P 1986 Spondyloarthropathies of childhood.
Pediatr. Clin. North Am. 33: 1079-1096.
-
Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loet X, Ravaud P, Claudepierre P, Miceli-Richard C, de Bandt M, Breban M, Maillefert JF, Masson C, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Combe B 2007 Recommendations of the French Society f
| |
